Innovation Pharmaceuticals Inc (IPIX)

[DesireToLearn]

Key findings presented include: transcriptomic analyses, demonstrating Kevetrin modulation of p53 signaling pathways; and induction of cell cycle arrest and apoptosis in Ovarian Cancer cell-lines and in xenograft tumors.

In a completed Phase 1 clinical trial, Kevetrin was well-tolerated with minimal adverse effects. A Phase 2a clinical trial in Ovarian Cancer is currently underway in which similar analyses of pathway modulations by Kevetrin are being explored directly using tumor biopsies before and after treatment.